| Our Products |
 |
|
 |
| |
| Funded through Governmental Grants, Development Partners and Investor Offerings |
| Key products prevent infections highly prevalent in human populations |
| » |
The common cold caused by Rhinovirus sp. |
| » |
Tooth decay caused by Streptococcus mutans |
|
|
|
| |
 |
|
|
|
 |
|
| Proof of concept and Phase I/II trials |
| » |
Status: completed |
| » |
Funded by NIH SBIR awards and initial commercial development partner ($3.5 million) |
| » |
Approved in European Union (EU) as Medical Device |
|
| |
| Targets: Final market formulation testing in EU; further clinical development in US |
| » |
Projected source of financing: marketing and development partner(s) in EU and US |
|
|
|
| |
| |
|
| CaroRxTM SIgA |
| |
| NOVEL THERAPY to eliminate S. mutans the CAUSE of DENTAL CARIES (tooth decay) |
|
| Medical device approval in EU US Phase I/IIa clinical completed |
|
 |
| |
|
|
 |
|
| |
|
|
|
|
 |
|
| Early proof of concept R&D |
| » |
Status: completed |
| » |
Funded by NIH SBIR awards ($1.55 million) |
|
| |
| Target: Complete preclinical and clinical Phase I/II clinical trial (University of Virginia) |
| » |
Projected source of financing. Primary use of Offering proceeds ($1.6 million) |
|
|
|
| |
|
|
| Rhinovirus: the most common cold |
| |
| 50% of adult colds – 25% of pediatric colds |
| » |
102 serotypes (91 bind to ICAM-1) |
| » |
1 billion colds per year in the US |
| » |
27 million office visits per year in the US |
|
|
| |
|
|
| sICAM-1 is Effective Decoy Receptor |
| |
| In vitro: 89 serotypes tested, all bound ICAM-1; median IC50 < 10 µg/ml |
 |
Crump et al. (1993) Antiviral Chem Chemother 4:323-327 |
|
| |
| In chimps: Therapy with 10 mg 0-10 min after exposure; sICAM-1 prevented infection with HRV16 |
|
Huguenel et al., (1997) Am J Resp Crit Care Med 155:1206-1210. |
|
| |
| In humans: sICAM-1 (4.4 mg/d); Reduced severity of HRV challeng. No adverse effects |
|
Turner et al., (1999) JAMA 281:1797-1804. |
|
|
| |
|
|
| RhinoRxTM for the Common Cold |
|
| ICAM-decoy blocks Rhinovirus Prevents infection/reduces duration |
|
| Blockbuster potential – 1 billion colds |
|
 |
| |
|
|
 |
|
| |
|
|
|
|
 |
|
| Early proof of concept R&D |
| » |
Status: completed |
| » |
Funded by NIH SBIR and Department of Defense awards ($830,000) |
|
| |
| Target: Complete preclinical and clinical (Phase I trial University of Maryland) |
| » |
Source of financing: NIH SBIR award (September 1, 2006 - $5.2 million) |
|
|
|
| |
|
|
| Botulinum neurotoxin A Category A Threat Agent |
|
| 3 Plantibodies Immediately protective |
|
| Exclusive LOI with University of California |
|
 |
|
|
 |
|
| |
|
|
|
|
 |
|
| Early proof of concept R&D |
| » |
Status: completed |
| » |
Funded by NIH SBIR award ($105,000) |
|
| |
| Target: Complete preclinical; submission of IND to FDA |
| » |
Source of financing: NIH SBIR award (June 1, 2006 - $3.5 million) |
|
|
|
| |
|
|
| Immunoadhesin IgG-CMG2 fusion AntaRx™ binds to PA; |
|
| Survival of Dutch-belted Rabbits Challenged with 100 LD50 B. anthracis Ames spores Ames spores via Intranasal Challenge and Immunized with AntaRx™ at time of challenge |
|
 |
|
|
 |
|
| |
|
